FIELD: chemistry.
SUBSTANCE: group of inventions refers to the chemical and pharmaceutical industry and is a method of treating Ph+ leukemia in a subject, comprising orally administering the pharmaceutical composition once daily, and the pharmaceutical composition itself in the form of capsules, characterized by the following composition and ratio of components, mass. %: active component: monomesylate – 3-(1,2,4-triazolo[4,3-a]pyridin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide 25–50 %; auxiliary components: lactose monohydrate 25–60 %; crospovidone 1.5–4 %; colloidal silicon dioxide 0.2–1 %; magnesium stearate 0.2–1 %; microcrystalline cellulose 0–30 %.
EFFECT: group of inventions allows to obtain a new pharmaceutical composition effective in the treatment of Ph+ leukemia, having optimal characteristics of stability and compatibility of the components; in addition, the composition allows to provide the optimal dosage in one unit of the drug, allows to provide an effective and safe dosing of the drug.
14 cl, 1 tbl, 2 ex
